CN113759064B - Thin-layer identification method for medicinal material carmine flower root and application thereof - Google Patents
Thin-layer identification method for medicinal material carmine flower root and application thereof Download PDFInfo
- Publication number
- CN113759064B CN113759064B CN202110177404.8A CN202110177404A CN113759064B CN 113759064 B CN113759064 B CN 113759064B CN 202110177404 A CN202110177404 A CN 202110177404A CN 113759064 B CN113759064 B CN 113759064B
- Authority
- CN
- China
- Prior art keywords
- medicinal material
- root
- sample
- thin
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000463 material Substances 0.000 title claims abstract description 125
- 238000000034 method Methods 0.000 title claims abstract description 68
- 235000012730 carminic acid Nutrition 0.000 title claims description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 159
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims abstract description 144
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 143
- 239000000243 solution Substances 0.000 claims abstract description 78
- 241000100151 Primula maximowiczii Species 0.000 claims abstract description 72
- 235000018173 Primula maximowiczii Nutrition 0.000 claims abstract description 72
- 239000002775 capsule Substances 0.000 claims abstract description 45
- 208000014617 hemorrhoid Diseases 0.000 claims abstract description 41
- 241000219470 Mirabilis Species 0.000 claims abstract description 40
- 238000004809 thin layer chromatography Methods 0.000 claims abstract description 38
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 28
- 238000004458 analytical method Methods 0.000 claims abstract description 24
- 239000012085 test solution Substances 0.000 claims abstract description 19
- LMKYZBGVKHTLTN-NKWVEPMBSA-N D-nopaline Chemical compound NC(=N)NCCC[C@@H](C(O)=O)N[C@@H](C(O)=O)CCC(O)=O LMKYZBGVKHTLTN-NKWVEPMBSA-N 0.000 claims abstract description 12
- 239000002904 solvent Substances 0.000 claims abstract description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 222
- 239000000523 sample Substances 0.000 claims description 169
- 239000003814 drug Substances 0.000 claims description 103
- 229940079593 drug Drugs 0.000 claims description 95
- 239000000843 powder Substances 0.000 claims description 40
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 36
- 238000001704 evaporation Methods 0.000 claims description 35
- 239000000706 filtrate Substances 0.000 claims description 35
- 238000001914 filtration Methods 0.000 claims description 35
- 238000011161 development Methods 0.000 claims description 34
- 229940076810 beta sitosterol Drugs 0.000 claims description 29
- 229950005143 sitosterol Drugs 0.000 claims description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- 239000002253 acid Substances 0.000 claims description 22
- 239000012488 sample solution Substances 0.000 claims description 22
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 18
- 235000019253 formic acid Nutrition 0.000 claims description 18
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 claims description 17
- QDFKFNAHVGPRBL-UHFFFAOYSA-N daucosterol Natural products CCC(CCC(C)C1CCC2C1CCC3C2(C)CC=C4CC(CCC34C)OC5OC(CO)C(O)C(O)C5O)C(C)C QDFKFNAHVGPRBL-UHFFFAOYSA-N 0.000 claims description 17
- 239000003960 organic solvent Substances 0.000 claims description 17
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 15
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 claims description 12
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 claims description 12
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 claims description 12
- ROAYSRAUMPWBQX-UHFFFAOYSA-N ethanol;sulfuric acid Chemical compound CCO.OS(O)(=O)=O ROAYSRAUMPWBQX-UHFFFAOYSA-N 0.000 claims description 12
- 150000007524 organic acids Chemical class 0.000 claims description 12
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 claims description 12
- 239000012088 reference solution Substances 0.000 claims description 11
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 10
- 238000007689 inspection Methods 0.000 claims description 10
- 239000000741 silica gel Substances 0.000 claims description 10
- 229910002027 silica gel Inorganic materials 0.000 claims description 10
- 239000004106 carminic acid Substances 0.000 claims description 6
- 229940080423 cochineal Drugs 0.000 claims description 6
- 230000004913 activation Effects 0.000 claims description 5
- 230000003213 activating effect Effects 0.000 claims description 4
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 claims description 4
- 239000004952 Polyamide Substances 0.000 claims description 3
- 229920002647 polyamide Polymers 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 238000007598 dipping method Methods 0.000 claims 1
- 238000000527 sonication Methods 0.000 claims 1
- 244000028344 Primula vulgaris Species 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 53
- 238000009210 therapy by ultrasound Methods 0.000 description 29
- 239000013558 reference substance Substances 0.000 description 25
- 244000017106 Bixa orellana Species 0.000 description 23
- 235000012665 annatto Nutrition 0.000 description 19
- 239000010362 annatto Substances 0.000 description 19
- 244000022198 Mirabilis jalapa Species 0.000 description 13
- 235000009053 Mirabilis jalapa Nutrition 0.000 description 13
- 239000013074 reference sample Substances 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 12
- 238000000926 separation method Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 238000005507 spraying Methods 0.000 description 6
- 230000007480 spreading Effects 0.000 description 6
- 241001071918 Heliotropium Species 0.000 description 5
- 238000007605 air drying Methods 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 239000003208 petroleum Substances 0.000 description 5
- 235000006010 Bixa orellana Nutrition 0.000 description 4
- 235000012978 bixa orellana Nutrition 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 101100408384 Danio rerio piwil2 gene Proteins 0.000 description 3
- 241000446313 Lamella Species 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- BLKPFVWYBFDTPX-UHFFFAOYSA-N 2-(6,6-dimethyl-4-bicyclo[3.1.1]hept-3-enyl)acetaldehyde Chemical compound C1C2C(C)(C)C1CC=C2CC=O BLKPFVWYBFDTPX-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 240000005220 Bischofia javanica Species 0.000 description 1
- 235000010893 Bischofia javanica Nutrition 0.000 description 1
- 240000008607 Opuntia megacantha Species 0.000 description 1
- 235000002840 Opuntia megacantha Nutrition 0.000 description 1
- 235000006538 Opuntia tuna Nutrition 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000002021 butanolic extract Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/90—Plate chromatography, e.g. thin layer or paper chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/90—Plate chromatography, e.g. thin layer or paper chromatography
- G01N30/94—Development
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/90—Plate chromatography, e.g. thin layer or paper chromatography
- G01N30/95—Detectors specially adapted therefor; Signal analysis
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a thin-layer identification method of a medicinal material common primrose root, which comprises the following steps: respectively pretreating a primula maximowiczii root sample to be identified in the same way to obtain a test solution, and pretreating a reference medicinal material sample to obtain a reference medicinal material solution; and carrying out thin-layer chromatography identification analysis on the test solution and the reference medicinal material solution; wherein, the step of the thin-layer chromatography identification analysis adopts toluene-ethyl acetate-acetone as a developing agent, and the volume ratio of the toluene, the ethyl acetate and the acetone is (1-5) to (1-5). The thin-layer identification method can also be applied to distinguishing the medicinal material nopaline root and the medicinal material himalayan Mirabilis root and identifying a hemorrhoid treatment capsule containing the medicinal material nopaline root. The identification method has the advantages of proper selection of the developing solvent, high identification efficiency, high identification precision and convenient operation.
Description
Technical Field
The invention relates to a Chinese herbal medicine identification method, in particular to a thin-layer identification method of a medicinal material primula maximowiczii root, a thin-layer identification method for distinguishing the medicinal material primula maximowiczii root from a medicinal material himalayan mirabilis root, a thin-layer identification method of a hemorrhoid treatment capsule containing the medicinal material primula maximowiczii root and application of the thin-layer identification method.
Background
The nopal root is dried root of Mirabilis jalapa L.of Mirabilis of Mirabilis. Collected in autumn and winter, removed fibrous root, cleaned, and sliced or directly dried. The primula maximowiczii root is also used as a drug for minority nationality in Guizhou province.
Mirabilis jalapa was originally recorded in Dian nan Ben Cao (bitter cloves) of Ming-Xian-lan Mao (1397-1476), which means that its flower has five colors and its root is used. Qing Dynasty Zhao Xuemin, the earliest used the name Mirabilis jalapa in Ben Cao gang mu Shi Yi. Mirabilis jalapa is used in folk, and has medical records in Shanxi Gan Ningqing Chinese herbal medicine selection, guizhou folk prescription and medicine Collection, fujian medicine Studies, tujian medicine Studies and national Chinese herbal medicine compilation. Modern researches find that the mirabilis jalapa root has the effects of resisting virus, resisting cancer, resisting tumors, resisting bacteria and reducing blood sugar. At present, mirabilis root is customarily called Bischofia indica root in Guizhou district and has been collected and loaded by quality Standard of traditional Chinese medicine and national medicine in Guizhou province (2003 edition). Mirabilis jalapa medicinal material is also collected in the Standard of Chinese medicinal materials in Yunnan province (2005 edition) (fourth volume Yi nationality medicine).
The existing identifying research of carmine root (Mirabilis asiatica root) (Lei Juntao et al, identifying research of Mirabilis asiatica root, anhui agricultural science, 2012,40 (9): 5191-5192, 5195) includes character identification, microscopic identification, physicochemical identification, thin layer identification and ultraviolet spectrum identification. Wherein, the thin layer identification only shows that the n-butanol extract on the thin layer plate has yellow brown spots separated out, and the chloroform extract and the petroleum ether extract have the same color spots at corresponding positions. However, the thin-layer identification method has the defects that a reference medicinal material, a reference substance and a specific developing agent are lacked, the identification precision is extremely low, the effective identification of the medicinal material annatto (the heliotrope root) cannot be realized, and the effective identification of the medicinal material annatto (the heliotrope root) and the similar medicinal material heliotrope himalayan cannot be realized.
Based on the reasons, the thin-layer identification method of the medicinal material carmine root (the Mirabilis jalapa Linn.) is required to be further researched so as to solve the problems that the existing thin-layer identification method is lack of a reference medicinal material, a reference substance and specific developing agent conditions and is extremely low in identification precision.
Disclosure of Invention
Based on the above, the main objective of the present invention is to provide a thin-layer identification method for the medicinal material primula maximowiczii root, a thin-layer identification method for distinguishing the medicinal material primula maximowiczii root from the medicinal material himalayan mirabilis root, a thin-layer identification method for the hemorrhoid treatment capsule containing the medicinal material primula maximowiczii root, and an application of the thin-layer identification method, so as to solve the problems that the existing thin-layer identification method in the prior art is lack of a reference medicinal material, a reference substance, specific developing agent conditions and extremely low in identification precision.
In order to achieve the above object, according to one aspect of the present invention, there is provided a thin layer identification method for a medicinal material primula maximowiczii root, comprising the steps of:
(1) Respectively pretreating a primula maximowiczii root sample to be identified in the same way to obtain a test solution, and pretreating a reference medicinal material sample to obtain a reference medicinal material solution; and
(2) Carrying out thin-layer chromatography identification analysis on the test solution and the reference solution;
wherein, the step of the thin-layer chromatography identification analysis adopts toluene-ethyl acetate-acetone as a developing agent, and the volume ratio of the toluene, the ethyl acetate and the acetone is (1-5) to (1-5).
According to another aspect of the present invention, there is provided a thin-layer identification method for distinguishing a medicinal material carmine root from a medicinal material heliotrope himalayan, comprising the steps of:
(1) Respectively pretreating a medicinal material primula maximowiczii root sample to obtain a primula maximowiczii root sample solution, and pretreating a medicinal material himalayan mirabilis root sample to obtain a himalayan mirabilis root sample solution in the same mode; and
(2) Carrying out thin-layer chromatography identification analysis on the primula maximowiczii root sample solution and the himalayan mirabilis root sample solution;
wherein, the step of the thin-layer chromatography identification analysis adopts toluene-ethyl acetate-acetone as a developing agent, and the volume ratio of the toluene, the ethyl acetate and the acetone is (1-5) to (1-5).
According to another aspect of the invention, there is provided a thin layer identification method of a hemorrhoid treatment capsule containing the medicinal material nopaline root, comprising the following steps:
(1) Respectively pretreating a hemorrhoid treatment capsule sample to be identified in the same way to obtain a test solution, and pretreating a reference medicinal material or a reference substance to obtain a reference medicinal material solution or a reference substance solution; and
(2) Carrying out thin-layer chromatography identification analysis on the test solution and the reference medicinal material solution or the reference solution;
wherein, the step of the thin-layer chromatography identification analysis adopts toluene-ethyl acetate-acetone as a developing agent, and the volume ratio of the toluene, the ethyl acetate and the acetone is (1-5) to (1-5).
Furthermore, the volume ratio of the toluene to the ethyl acetate to the acetone is (1-4) to (2-5).
Furthermore, the volume ratio of the toluene to the ethyl acetate to the acetone is (1-4) to (2-5).
Furthermore, the volume ratio of the toluene to the ethyl acetate to the acetone is (1-4) to (2-3).
Furthermore, the volume ratio of the toluene to the ethyl acetate to the acetone is (2-4) to (2-3).
Furthermore, the volume ratio of the toluene to the ethyl acetate to the acetone is 4 (2-4) to 2.
Further, the volume ratio of toluene, ethyl acetate and acetone was 4.
Further, the developing agent further comprises an acid.
Further, the acid is an organic acid.
Further, the organic acid is formic acid and/or acetic acid.
Further, the acid is present in a volume fraction of 2.5% to 3.5% relative to the sum of the volumes of toluene, ethyl acetate and acetone.
Further, the thin layer identification method further comprises a thin layer plate activation step.
Further, the thin layer plate activating step includes activating the thin layer plate at 100 to 120 ℃ for 20 to 60 minutes.
Further, the thin layer plate is selected from silica gel G thin layer plate and silica gel GF 254 Thin layer plate, silica gel H thin layer plate, silica gel HF 254 At least one of a laminate sheet and a polyamide laminate sheet.
Further, the inspection conditions in the step of the thin layer chromatography differential analysis are: and (4) observing under visible light.
Further, taking out the developed thin-layer plate during inspection, airing, and spraying a 5-10% sulfuric acid ethanol solution or a 5-25% phosphomolybdic acid ethanol solution for color development.
Furthermore, the developed thin-layer plate is taken out during inspection, dried and sprayed with 5-10% sulfuric acid ethanol solution for color development.
Further, the pretreatment comprises the steps of adding an organic solvent into sample powder or reference powder for treatment for 5-50 minutes, filtering, evaporating filtrate to dryness, and dissolving residues by adding the organic solvent to obtain a corresponding sample solution or reference solution.
Further, the sample solution is spotted in an amount of 3. Mu.L to 10. Mu.L.
Further, the spotting amount of the control solution was 5. Mu.L to 10. Mu.L.
Further, the concentration of the control solution is 0.15mg/mL to 0.30mg/mL.
Further, the organic solvent is any one or a mixture of more than two of methanol, ethanol, n-butanol and ethyl acetate.
Further, the treatment time is 10 to 45 minutes.
Further, the treatment time is 20 to 30 minutes.
Further, the treatment method comprises any one or more of ultrasound, reflux, decoction and immersion.
Further, the reference substance is daucosterol and/or beta-sitosterol.
Further, the reference medicinal material is a carmine root reference medicinal material.
According to another aspect of the invention, the thin-layer identification method is used for identifying the medicinal material nopaline root or identifying the hemorrhoid treatment capsule containing the medicinal material nopaline root.
According to another aspect of the present invention, there is provided a kit for identifying a medicinal material annatto or a hemorrhoid treatment capsule containing the medicinal material annatto, which includes a lamella plate and a developing agent.
Further, toluene-ethyl acetate-acetone was used as the developing solvent.
Furthermore, the volume ratio of the toluene to the ethyl acetate to the acetone is (1-5) to (1-5).
Furthermore, the volume ratio of the toluene to the ethyl acetate to the acetone is (1-4) to (2-5).
Furthermore, the volume ratio of the toluene to the ethyl acetate to the acetone is (1-4) to (2-5).
Furthermore, the volume ratio of the toluene to the ethyl acetate to the acetone is (1-4) to (2-3).
Furthermore, the volume ratio of the toluene to the ethyl acetate to the acetone is (2-4) to (2-3).
Furthermore, the volume ratio of the toluene to the ethyl acetate to the acetone is 4 (2-4) to 2.
Further, the volume ratio of toluene, ethyl acetate and acetone was 4.
Further, the developing agent further comprises an acid.
Further, the acid is an organic acid.
Further, the organic acid is formic acid and/or acetic acid.
Further, the acid is present in a volume fraction of 2.5% to 3.5% relative to the sum of the volumes of toluene, ethyl acetate and acetone.
By applying the technical scheme of the invention, the thin-layer identification method has the advantages of proper selection of the developing solvent, high identification efficiency, high identification precision and convenient operation, thereby well solving the problems of lack of reference medicinal materials, lack of reference substances, lack of specific developing solvent conditions and extremely low identification precision of the existing thin-layer identification method.
Drawings
In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the drawings required to be used in the description of the embodiments are briefly introduced below, and it is obvious that the drawings in the description below are only some embodiments of the present invention, and it is obvious for those skilled in the art to obtain other drawings based on the drawings without departing from the scope of the claimed invention.
FIG. 1 is a development of thin layer chromatography of example one (I), wherein number 1- -daucosterol; number 2- - -beta-sitosterol; number 3-control drug (i.e. primula maximowiczii root control drug sample) 1; number 4-control drug (i.e. primula maximowiczii root control drug sample) 2; number 5- -reference drug to be distinguished (i.e. Himalayan Mirabilis root reference sample); no. 6- -sample of test sample (i.e. Capsule for treating hemorrhoid).
FIG. 2 is a development of thin layer chromatography of example one (II), in which 1- - -daucosterol; number 2- - -beta-sitosterol; number 3-reference drug (i.e. primula maximowiczii root reference drug sample) 1; number 4-control drug (i.e. primula maximowiczii root control drug sample) 2; number 5- -reference drug to be distinguished (i.e. Himalayan Mirabilis root reference sample); no. 6- -sample of test sample (i.e. Capsule for treating hemorrhoid).
FIG. 3 is a developed view of TLC of example one (III), in which number 1- -daucosterol; number 2- - -beta-sitosterol; number 3-control drug (i.e. primula maximowiczii root control drug sample) 1; number 4-control drug (i.e. primula maximowiczii root control drug sample) 2; number 5- -reference drug to be distinguished (i.e. Himalayan Mirabilis root reference sample); no. 6- -sample of test sample (i.e. Capsule for treating hemorrhoid).
FIG. 4 is a development of thin layer chromatography of example two (one), in which number 1- -daucosterol; number 2- - -beta-sitosterol; number 3-reference drug (i.e. primula maximowiczii root reference drug sample) 1; number 4-control drug (i.e. primula maximowiczii root control drug sample) 2; number 5- -reference drug to be distinguished (i.e. Himalayan Mirabilis root reference sample); number 6- -test sample (i.e., mediterranean Mirabilis root sample); no. 7- -sample to be tested (i.e. Capsule sample for treating hemorrhoid).
FIG. 5 is a development of thin layer chromatography of example two (II), in which number 1- -daucosterol; number 2- - -beta-sitosterol; number 3-control drug (i.e. primula maximowiczii root control drug sample) 1; number 4-control drug (i.e. primula maximowiczii root control drug sample) 2; number 5- -reference drug to be distinguished (i.e. Himalayan Mirabilis root reference sample); number 6- - -test sample (i.e. the medicinal material himalayan zili root sample); no. 7- -test sample (i.e. Capsule sample for treating hemorrhoid).
FIG. 6 is a development of thin layer chromatography of example two (III), in which number 1- -daucosterol; number 2- - -beta-sitosterol; number 3-reference drug (i.e. primula maximowiczii root reference drug sample) 1; number 4-control drug (i.e. primula maximowiczii root control drug sample) 2; number 5- -reference drug to be distinguished (i.e. Himalayan Mirabilis root reference sample); number 6- - -test sample (i.e. the medicinal material himalayan zili root sample); no. 7- -test sample (i.e. Capsule sample for treating hemorrhoid).
FIG. 7 is a development of thin layer chromatography of example three (one), in which number 1- -daucosterol; number 2- - -beta-sitosterol; number 3-control drug (i.e. primula maximowiczii root control drug sample) 1; number 4-control drug (i.e. primula maximowiczii root control drug sample) 2; number 5- -reference drug to be distinguished (i.e. Himalayan Mirabilis root reference sample); no. 6- -sample of test sample (i.e. Capsule for treating hemorrhoid).
FIG. 8 is a development of thin layer chromatography of example III (II) in which the number 1- - -daucosterol; number 2- - -beta-sitosterol; number 3-reference drug (i.e. primula maximowiczii root reference drug sample) 1; number 4-control drug (i.e. primula maximowiczii root control drug sample) 2; number 5- -reference drug to be distinguished (i.e. Himalayan Mirabilis root reference sample); no. 6- -sample to be tested (i.e. Capsule sample for treating hemorrhoid).
FIG. 9 is a development of thin layer chromatography of example four (one), in which number 1- -daucosterol; number 2- - -beta-sitosterol; number 3-reference drug (i.e. primula maximowiczii root reference drug sample) 1; number 4-control drug (i.e. primula maximowiczii root control drug sample) 2; number 5- -reference medicinal material to be distinguished (i.e. Himalayan Mirabilis root reference sample); number 6- - -test sample (i.e. the medicinal material himalayan zili root sample); no. 7- -test sample (i.e. Capsule sample for treating hemorrhoid).
FIG. 10 is a development of thin layer chromatography of example four (II), in which the number 1- -daucosterol; number 2- - -beta-sitosterol; number 3-reference drug (i.e. primula maximowiczii root reference drug sample) 1; number 4-control drug (i.e. primula maximowiczii root control drug sample) 2; number 5- -reference medicinal material to be distinguished (i.e. Himalayan Mirabilis root reference sample); number 6- -test sample (i.e., mediterranean Mirabilis root sample); no. 7- -test sample (i.e. Capsule sample for treating hemorrhoid).
FIG. 11 is a development of thin layer chromatography of example four (III), in which number 1- -daucosterol; number 2- - -beta-sitosterol; number 3-reference drug (i.e. primula maximowiczii root reference drug sample) 1; number 4-control drug (i.e. primula maximowiczii root control drug sample) 2; number 5- -reference medicinal material to be distinguished (i.e. Himalayan Mirabilis root reference sample); number 6- -test sample (i.e., mediterranean Mirabilis root sample); no. 7- -sample to be tested (i.e. Capsule sample for treating hemorrhoid).
FIG. 12 is a development of thin layer chromatography of example five, in which number 1- -daucosterol; number 2- - -beta-sitosterol; number 3-reference drug (i.e. primula maximowiczii root reference drug sample) 1; number 4-control drug (i.e. primula maximowiczii root control drug sample) 2; number 5-control drug (i.e. primula maximowiczii root control drug sample) 3; number 6-sample (crude drug annatto root sample) 1; number 7- -sample to be tested (sample of primula maximowiczii root); number 8-sample (crude drug annatto root sample) 3; number 9-sample (sample of primula maximowiczii root) 4; number 10-sample (sample of primula maximowiczii root) 5; number 11- -sample to be tested (sample of primula maximowiczii root); number 12- -sample (sample of primula maximowiczii root) 7; no. 13- -sample to be tested (sample of Bixa orellana root).
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are some, not all, embodiments of the present invention. All other embodiments, which can be obtained by a person skilled in the art without making any creative effort based on the embodiments in the present invention, belong to the protection scope of the present invention.
As described in the background art section, the existing thin layer identification methods lack the control medicinal materials, lack the control products, lack the specific developing agent conditions, and have extremely low identification accuracy. In order to solve the problems, the invention provides a thin-layer identification method of a medicinal material common primrose root, which comprises the following steps:
(1) Respectively pretreating a medicinal material primula maximowiczii root sample to be identified in the same way to obtain a test solution, and pretreating a reference medicinal material sample to obtain a reference medicinal material solution; and
(2) Carrying out thin-layer chromatography identification analysis on the test solution and the reference solution;
wherein, the step of the thin-layer chromatography identification analysis adopts toluene-ethyl acetate-acetone as a developing agent, and the volume ratio of the toluene, the ethyl acetate and the acetone is (1-5) to (1-5).
According to another aspect of the present invention, there is provided a thin-layer identification method for distinguishing a medicinal material carmine root from a medicinal material heliotrope himalayan, comprising the steps of:
(1) Respectively pretreating a medicinal material primula maximowiczii root sample to obtain a primula maximowiczii root sample solution, and pretreating a medicinal material himalayan mirabilis root sample to obtain a himalayan mirabilis root sample solution in the same mode; and
(2) Carrying out thin-layer chromatography identification analysis on the annatto sample solution and the himalayan mirabilis root sample solution;
wherein, the step of the thin-layer chromatography identification analysis adopts toluene-ethyl acetate-acetone as a developing agent, and the volume ratio of the toluene, the ethyl acetate and the acetone is (1-5) to (1-5).
According to another aspect of the invention, there is provided a thin layer identification method of a hemorrhoid treatment capsule containing the medicinal material nopaline root, comprising the following steps:
(1) Respectively pretreating a hemorrhoid treatment capsule sample to be identified in the same way to obtain a test solution, and pretreating a reference medicinal material or a reference substance to obtain a reference medicinal material solution or a reference substance solution; and
(2) Carrying out thin-layer chromatography identification analysis on the test solution and the reference medicinal material solution or the reference solution;
wherein, the step of the thin-layer chromatography identification analysis adopts toluene-ethyl acetate-acetone as a developing agent, and the volume ratio of the toluene, the ethyl acetate and the acetone is (1-5) to (1-5).
According to the method for simultaneously identifying the annatto root, the himalayan Mirabilis root and the hemorrhoid treatment capsule sample, the same pretreatment method is adopted for the annatto root, the himalayan Mirabilis root and the hemorrhoid treatment capsule sample, and a specific developing agent system is selected, so that various components in the annatto root, the himalayan Mirabilis root and the hemorrhoid treatment capsule sample can be well separated, and simultaneous identification is realized. In the chromatogram of each test sample, spots with the same color are displayed at the positions corresponding to the chromatogram of the reference substance or the chromatogram of the reference medicinal material, and strong specificity is displayed. Meanwhile, the method simplifies the operation process, reduces the time required by identification, improves the working efficiency and reduces the detection cost.
In order to achieve better separation between spots during thin layer development, in a preferred embodiment the volume ratio of toluene, ethyl acetate and acetone is (1-4): (2-5).
In a preferred embodiment, the volume ratio of toluene, ethyl acetate and acetone is (1-4) to (2-5).
In a preferred embodiment, the volume ratio of toluene, ethyl acetate and acetone is (1-4) to (2-5).
In a preferred embodiment, the volume ratio of toluene, ethyl acetate and acetone is (1-4) to (2-3).
In a preferred embodiment, the volume ratio of toluene, ethyl acetate and acetone is (2-4) to (2-3).
In a preferred embodiment, the volume ratio of toluene, ethyl acetate and acetone is 4 (2-4) to 2.
In a preferred embodiment, the volume ratio of toluene, ethyl acetate and acetone is 4.
In order to prevent smearing of the spots during the spreading of the sheet, in a preferred embodiment, the spreading agent further comprises an acid.
In a preferred embodiment, the acid is an organic acid.
In a preferred embodiment, the organic acid is formic acid and/or acetic acid.
In a preferred embodiment, the acid is present in a volume fraction of 2.5% to 3.5% relative to the sum of the volumes of toluene, ethyl acetate and acetone.
In order to remove volatile impurities and moisture adsorbed on the thin layer plate and improve separation efficiency, in a preferred embodiment, the thin layer identification method further comprises a thin layer plate activation step.
To further enhance the efficiency of the separation of spots on the lamina plate, in a preferred embodiment, the lamina plate activation step comprises activating the lamina plate at 100 ℃ to 120 ℃ for 20 minutes to 60 minutes.
In a preferred embodiment, the lamella plates are selected from the group consisting of silica gel G lamella plates, silica gel GF 254 Thin layer plate, silica gel H thin layer plate, silica gel HF 254 At least one of a laminate sheet and a polyamide laminate sheet.
In a preferred embodiment, the inspection conditions in the step of TLC differential analysis are: and (4) observing under visible light.
In a preferred embodiment, the developed thin-layer plate is taken out during the inspection, dried, sprayed with 5 to 10 percent sulfuric acid ethanol solution or 5 to 25 percent phosphomolybdic acid ethanol solution for color development.
In a preferred embodiment, the developed thin-layer plate is taken out during the inspection, dried and sprayed with 5-10% sulfuric acid ethanol solution for color development.
In a preferred embodiment, the pretreatment comprises adding organic solvent into the sample powder or the reference powder for 5-50 minutes, filtering, evaporating the filtrate, and dissolving the residue with organic solvent to obtain the corresponding sample solution or the reference solution.
In a preferred embodiment, the sample solution is applied in an amount of 3. Mu.L to 10. Mu.L.
In order to allow the sample solution to show clear and non-streaking spots after thin layer development, in a preferred embodiment, the spots are most clear when the sample amount of the annatto root sample is 10 μ L; the hemorrhoid treating capsule (Miao medicine containing primula maximowiczii root) is most suitable when the sample amount is 3 μ L.
In order to allow the control solution to show clear and non-streaking spots after thin layer development, in a preferred embodiment, the control solution is spotted in an amount of 5 μ L to 10 μ L.
In a preferred embodiment, the concentration of the control solution is 0.15mg/mL to 0.30mg/mL.
In a preferred embodiment, the organic solvent is any one or a mixture of two or more of methanol, ethanol, n-butanol and ethyl acetate.
In a preferred embodiment, the treatment time is 10 to 45 minutes.
In order to allow the sample or control solution to show clear and moderate spots after thin layer development, the treatment time is in a preferred embodiment 30 to 40 minutes.
In a preferred embodiment, the treatment method is any one or more of ultrasound, reflux, decoction and immersion.
In a preferred embodiment, the control is daucosterol and/or beta-sitosterol.
In a preferred embodiment, the control drug is a cochineal root control drug.
According to another aspect of the invention, the thin-layer identification method is used for identifying the medicinal material nopaline root or identifying the hemorrhoid treatment capsule containing the medicinal material nopaline root.
According to another aspect of the present invention, there is provided a kit for identifying a medicinal material annatto or a hemorrhoid treatment capsule containing the medicinal material annatto, including a thin layer plate and a developing agent.
In a preferred embodiment, toluene-ethyl acetate-acetone is used as the developing solvent.
In a preferred embodiment, the volume ratio of toluene, ethyl acetate and acetone is (1-5) to (1-5).
In order to achieve better separation between spots during thin layer development, in a preferred embodiment the volume ratio of toluene, ethyl acetate and acetone is (1-4): (2-5).
In a preferred embodiment, the volume ratio of toluene, ethyl acetate and acetone is (1-4) to (2-5).
In a preferred embodiment, the volume ratio of toluene, ethyl acetate and acetone is (1-4) to (2-3).
In a preferred embodiment, the volume ratio of toluene, ethyl acetate and acetone is (2-4) to (2-3).
In a preferred embodiment, the volume ratio of toluene, ethyl acetate and acetone is 4 (2-4): 2.
In a preferred embodiment, the volume ratio of toluene, ethyl acetate and acetone is 4.
In order to prevent smearing of the spots during the spreading of the sheet, in a preferred embodiment, the spreading agent further comprises an acid.
In a preferred embodiment, the acid is an organic acid.
In a preferred embodiment, the organic acid is formic acid and/or acetic acid.
In a preferred embodiment, the acid is present in a volume fraction of 2.5% to 3.5% relative to the sum of the volumes of toluene, ethyl acetate and acetone.
It should be noted that the embodiments and features of the embodiments in the present application may be combined with each other without conflict. The present invention will be described in detail with reference to examples.
The present invention is described in further detail below with reference to specific examples, which are not to be construed as limiting the scope of the invention as claimed herein.
The identification method of the invention comprises the following steps:
pretreating the test sample, the reference medicinal material and the reference substance respectively, and identifying by thin layer chromatography. Wherein, the pretreatment step can adopt the pretreatment means in the prior art.
Specifically, the identification method of the present invention specifically comprises the steps of:
1. preparation of a test solution:
taking the powder of a test sample (i.e. a sample of medicinal material carmine root or a sample of medicinal material himalayan Mirabilis root or a sample of medicinal material hemorrhoid treating capsule) and adding an organic solvent for treating for 5-50 minutes, filtering, evaporating the filtrate to dryness, and dissolving the residue with the organic solvent to obtain a corresponding test sample solution.
2. Preparation of reference drug solution:
preparing reference medicinal material solution from powder of reference medicinal material (i.e. primula maximowiczii root reference medicinal material sample) according to the preparation method of test solution.
3. Preparation of reference medicinal material solution to be distinguished
Taking the powder of the reference medicinal material to be distinguished (i.e. the reference medicinal material sample of Himalayan Mirabilis root) and preparing into the solution to be distinguished according to the preparation method of the test solution.
4. Preparation of control solutions:
preparing reference substance (daucosterol and beta-sitosterol) powder into corresponding reference substance solution according to the preparation method of the test substance solution.
5. Performing thin-layer chromatography analysis on the test solution, the reference medicinal material solution, the solution to be distinguished and the reference solution by adopting a thin-layer chromatography identification method:
the thin layer conditions were as follows:
thin-layer plate: silica gel G thin layer plate;
sample application: sample application of the test solution, the reference solution and the reference solution is 1-10 mul;
developing agent: toluene in the volume ratio of (1-5) to (1-5): ethyl acetate: acetone;
the unfolding mode is as follows: upward expansion;
and (6) inspection: observing under visible light;
and (3) chromatographic identification: and in the chromatogram of the test sample, if spots with the same color appear at the positions corresponding to the chromatograms of the reference medicinal materials or the reference substances, the test sample is a qualified product.
The following materials can be selected as the test materials used in the present invention, but the actual implementation is not limited to the following materials:
the instrument comprises the following steps: a rotary evaporator (EYELA, OSB-2100), a developer motor nebulizer (CAMAG, CH-4132 MUTTENZ), an oven (Zhongxing Wei, 101-1 AB) and an analytical balance (Yokov, YP 30002).
Reagent: silica gel G thin layer plate, produced by Qingdao Shenghai fine silica gel chemical Co., ltd, with plate specification of 100X 100mm and thickness of 0.20-0.25mm. Methanol, toluene, ethyl acetate, acetone, formic acid, concentrated sulfuric acid and absolute ethyl alcohol, all of which are analytically pure.
1-8 parts of test sample (medicinal material carmine flower root sample): the information is shown in table 1 below.
TABLE 1 Bixa orellana root sample information sheet
Test article (medicinal material himalayas Mirabilis jalapa sample): collected in 2019 from Sizang Linzhi, under the batch number 2019001.
Test article (hemorrhoid treating capsule sample): the Miao medicine containing the primula maximowiczii roots is produced by Guizhou Fuhua pharmaceutical industry, namely, the Limited liability company, and the batch number is 20180504.
1-3 of a control medicinal material (a cochineal flower root control medicinal material sample): the information is shown in the following table 2, and is developed according to the first research and development guiding principles (trial) of national drug reference medicinal materials in the Zhongzhong college.
TABLE 2 Bixa orellana root sample information sheet
The reference medicinal materials to be distinguished (i.e. the himalayan Mirabilis javanica reference medicinal material sample) are: purchased at the institute for testing and testing of Chinese food and drug, batch number: 121395-201303.
Comparison products: a daucosterol control product (HPLC is more than or equal to 98 percent, purchased from Shanghai-sourced leaf Biotechnology Co., ltd., batch number: P26F9F 54684) and a beta-sitosterol control product (the content is 97 percent, purchased from China food and drug testing institute, batch number: 110851-201608).
Example one
In this example, the effect of different developing agents on the results of the present technical solution is studied to further explain the present technical solution.
(1) Sample preparation:
Number 2- - -beta-sitosterol: taking beta-sitosterol reference substance, adding methanol to prepare a solution containing 0.2mg per 1ml, and using the solution as a reference substance solution. The concentration of the control in this test was 0.1956mg/mL.
Number 3-control drug (i.e. primula maximowiczii root control drug sample) 1: taking 1g of the powder, adding 10ml of methanol, performing ultrasonic treatment for 30min, filtering, evaporating the filtrate to dryness, and dissolving 1ml of methanol.
Number 4-control drug (i.e. primula maximowiczii root control drug sample) 2: taking 1g of the powder, adding 10ml of methanol, performing ultrasonic treatment for 30min, filtering, evaporating the filtrate to dryness, and dissolving 1ml of methanol.
Number 5-reference medicinal material to be distinguished (i.e. himalayan Mirabilis jalapa reference medicinal material sample): taking 1g of the powder, adding 10ml of methanol, performing ultrasonic treatment for 30min, filtering, evaporating the filtrate to dryness, and dissolving 1ml of methanol.
No. 6- -test article (i.e. hemorrhoid treating capsule sample): taking 1 capsule for treating hemorrhoid, opening the capsule, weighing about 0.5g of powder, adding 10ml of methanol, performing ultrasonic treatment for 30min, filtering, evaporating filtrate to dryness, and dissolving 1ml of methanol.
(2) Unfolding the system:
1. petroleum ether-ethyl acetate-acetone (5;
2. toluene-ethyl acetate-acetone (1;
3. toluene-ethyl acetate-acetone (5.
(3) The color development method comprises the following steps: taking out, air drying, spraying 5% sulphuric acid ethanol solution, and heating at 105 deg.C until the spots are clearly developed.
(4) And (3) test results:
in a developing system of petroleum ether-ethyl acetate-acetone (5; in a development system of toluene-ethyl acetate-acetone (1; in a development system of toluene-ethyl acetate-acetone (5.
Example two
In order to further optimize the toluene-ethyl acetate-acetone developer system, the present example further studies the effect of different developers on the results of the present technical solution, so as to further explain the present technical solution.
(1) Sample preparation:
Number 2- - -beta-sitosterol: taking beta-sitosterol reference substance, adding methanol to prepare a solution containing 0.2mg per 1ml, and using the solution as a reference substance solution. The concentration of the control in this test was 0.1956mg/mL.
Number 3-control drug (i.e. primula maximowiczii root control drug sample) 1: taking 1g of the powder, adding 10ml of methanol, performing ultrasonic treatment for 30min, filtering, evaporating the filtrate to dryness, and dissolving 1ml of methanol.
Number 4-control drug (i.e. primula maximowiczii root control drug sample) 2: taking 1g of the powder, adding 10ml of methanol, performing ultrasonic treatment for 30min, filtering, evaporating the filtrate to dryness, and dissolving 1ml of methanol.
Number 5-reference medicinal material to be distinguished (i.e. himalayan Mirabilis jalapa reference medicinal material sample): taking 1g of the powder, adding 10ml of methanol, performing ultrasonic treatment for 30min, filtering, evaporating the filtrate to dryness, and dissolving 1ml of methanol.
Number 6- -test sample (i.e. medicinal material himalayas mirabilis root sample): taking 1g of the powder, adding 10ml of methanol, performing ultrasonic treatment for 30min, filtering, evaporating the filtrate to dryness, and dissolving 1ml of methanol.
No. 7- -test sample (i.e. hemorrhoid treating capsule sample): taking 1 capsule for treating hemorrhoid, opening the capsule, weighing about 0.5g of powder, adding 10ml of methanol, performing ultrasonic treatment for 30min, filtering, evaporating the filtrate to dryness, and dissolving 1ml of methanol.
(2) Unfolding the system:
1. toluene-ethyl acetate-acetone (5;
2. toluene-ethyl acetate-acetone (4;
3. toluene-ethyl acetate-acetone (4.
(3) The color development method comprises the following steps: taking out, air drying, spraying 5% sulphuric acid ethanol solution, and heating at 105 deg.C until the spots are clearly developed.
(4) And (3) test results:
in a development system with 0.5ml formic acid in toluene-ethyl acetate-acetone (5; in a development system with 0.5ml formic acid in toluene-ethyl acetate-acetone (4; in a development system with 0.5ml formic acid in toluene-ethyl acetate-acetone (4; the hemorrhoid treatment capsule sample is well separated, and has corresponding spots with the reference sample and the primula maximowiczii reference sample; furthermore, the primula maximowiczii root and the himalayan mirabilis root are clearly different, and the results are shown in fig. 6.
EXAMPLE III
In this embodiment, the influence of different color developers on the results of the technical scheme is studied to further explain the technical scheme.
(1) Sample preparation:
Number 2- - -beta-sitosterol: taking beta-sitosterol reference substance, adding methanol to obtain solution containing 0.2mg per 1ml, and using as reference substance solution. The concentration of the control in this test was 0.1956mg/mL.
Number 4-control drug (i.e. primula maximowiczii root control drug sample) 2: taking 1g of the powder, adding 10ml of methanol, performing ultrasonic treatment for 30min, filtering, evaporating the filtrate to dryness, and dissolving 1ml of methanol.
Number 5-reference medicinal material to be distinguished (i.e. himalayan Mirabilis jalapa reference medicinal material sample): taking 1g of the powder, adding 10ml of methanol, performing ultrasonic treatment for 30min, filtering, evaporating the filtrate to dryness, and dissolving 1ml of methanol.
No. 6- -test article (hemorrhoid treating capsule sample): taking 1 capsule for treating hemorrhoid, opening the capsule, weighing about 0.5g of powder, adding 10ml of methanol, performing ultrasonic treatment for 30min, filtering, evaporating the filtrate to dryness, and dissolving 1ml of methanol.
(2) Unfolding the system: petroleum ether-ethyl acetate-acetone (5;
(3) The color development method comprises the following steps: taking out, air drying, spraying 5% sulphuric acid ethanol solution and 25% phosphomolybdic acid ethanol solution, respectively, and heating at 105 deg.C until the spots are clearly developed.
(4) And (3) test results: in petroleum ether-ethyl acetate-acetone (5: 5% sulfuric acid ethanol solution is more convenient for identification.
Example four
In this example, the influence of different formic acid addition amounts on the results of the present technical solution is studied to further explain the present technical solution.
(1) Sample preparation:
Number 2- - -beta-sitosterol: taking beta-sitosterol reference substance, adding methanol to obtain solution containing 0.2mg per 1ml, and using as reference substance solution. The concentration of the control in the test is 0.1956mg/mL.
Number 3-control drug (i.e. primula maximowiczii root control drug sample) 1: taking 1g of the powder, adding 10ml of methanol, performing ultrasonic treatment for 30min, filtering, evaporating the filtrate to dryness, and dissolving 1ml of methanol.
Number 4-control drug (i.e. primula maximowiczii root control drug sample) 2: taking 1g of the powder, adding 10ml of methanol, performing ultrasonic treatment for 30min, filtering, evaporating the filtrate to dryness, and dissolving 1ml of methanol.
Number 5-reference medicinal material to be distinguished (i.e. himalayan Mirabilis jalapa reference medicinal material sample): taking 1g of the powder, adding 10ml of methanol, performing ultrasonic treatment for 30min, filtering, evaporating the filtrate to dryness, and dissolving 1ml of methanol.
No. 6- - -test sample (i.e. the medicinal material of the himalayas mirabilis jalapa sample): taking 1g of the powder, adding 10ml of methanol, performing ultrasonic treatment for 30min, filtering, evaporating the filtrate to dryness, and dissolving 1ml of methanol.
No. 7- -test sample (i.e. hemorrhoid treating capsule sample): taking 1 capsule for treating hemorrhoid, opening the capsule, weighing about 0.5g of powder, adding 10ml of methanol, performing ultrasonic treatment for 30min, filtering, evaporating filtrate to dryness, and dissolving 1ml of methanol.
(2) Unfolding the system:
1. toluene-ethyl acetate-acetone (4);
2. toluene-ethyl acetate-acetone (4);
3. toluene-ethyl acetate-acetone (4.
(3) The color development method comprises the following steps: taking out, air drying, spraying 5% sulphuric acid ethanol solution, and heating at 105 deg.C until the spots are clearly developed.
(4) And (3) test results:
the content of formic acid has influence on the development result, the development system without formic acid has general separation result, the requirement of identifying medicinal materials can be basically realized, and the result is shown in figure 9; when the volume percentage of formic acid is about 0.83%, the separation effect is the same and general, the requirement of identifying the medicinal materials can be basically realized, and the result is shown in figure 10; when the volume ratio of formic acid is 2.5%, the separation effect is good, the spots are clear, the medicinal materials can be well identified, and the result is shown in fig. 11.
In the first, second and third examples, 0.5ml formic acid and 0.5ml formic acid developing agent are added into the prepared toluene-ethyl acetate-acetone, and the volume of the formic acid accounts for 2.44-3.45% of the sum of the volumes of the three solvents.
EXAMPLE five
The thin layer identification of the annatto roots in different producing areas is carried out by using the spreading system 1 in the fourth embodiment as the spreading agent condition, so as to further explain the technical scheme.
(1) Sample preparation:
Number 2- - -beta-sitosterol: taking beta-sitosterol reference substance, adding methanol to prepare a solution containing 0.2mg per 1ml, and using the solution as a reference substance solution. The concentration of the control in the test is 0.1956mg/mL.
Number 3-control drug (i.e. primula maximowiczii root control drug sample) 1: taking 1g of the powder, adding 10ml of methanol, performing ultrasonic treatment for 30min, filtering, evaporating the filtrate to dryness, and dissolving 1ml of methanol.
Number 4-control drug (i.e. primula maximowiczii root control drug sample) 2: taking 1g of the powder, adding 10ml of methanol, performing ultrasonic treatment for 30min, filtering, evaporating the filtrate to dryness, and dissolving 1ml of methanol.
Number 5-control drug (i.e. primula maximowiczii root control drug sample) 3: taking 1g of the powder, adding 10ml of methanol, performing ultrasonic treatment for 30min, filtering, evaporating the filtrate to dryness, and dissolving 1ml of methanol.
Number 6- - -test sample (medicinal material primula maximowiczii root sample) 1: taking 1g of the powder, adding 10ml of methanol, performing ultrasonic treatment for 30min, filtering, evaporating the filtrate to dryness, and dissolving 1ml of methanol.
Number 7- -test sample (crude drug cochineal flower root sample) 2: taking 1g of the powder, adding 10ml of methanol, performing ultrasonic treatment for 30min, filtering, evaporating the filtrate to dryness, and dissolving 1ml of methanol.
Number 8-sample (crude drug annatto root sample) 3: taking 1g of the powder, adding 10ml of methanol, performing ultrasonic treatment for 30min, filtering, evaporating the filtrate to dryness, and dissolving 1ml of methanol.
Number 9- -sample to be tested (crude drug annatto root sample) 4: taking 1g of the powder, adding 10ml of methanol, performing ultrasonic treatment for 30min, filtering, evaporating the filtrate to dryness, and dissolving 1ml of methanol.
Number 10- -test sample (crude drug annatto root sample) 5: taking 1g of the powder, adding 10ml of methanol, performing ultrasonic treatment for 30min, filtering, evaporating the filtrate to dryness, and dissolving 1ml of methanol.
Number 12- -test sample (crude drug annatto root sample) 7: taking 1g of the powder, adding 10ml of methanol, performing ultrasonic treatment for 30min, filtering, evaporating the filtrate to dryness, and dissolving 1ml of methanol.
Number 13- -sample to be tested (crude annatto root sample) 8: taking 1g of the powder, adding 10ml of methanol, performing ultrasonic treatment for 30min, filtering, evaporating the filtrate to dryness, and dissolving 1ml of methanol.
(2) Unfolding the system:
toluene-ethyl acetate-acetone (4.
(3) The color development method comprises the following steps: taking out, air drying, spraying 5% sulphuric acid ethanol solution, and heating at 105 deg.C until the spots are clearly developed.
(4) And (3) test results:
as shown in figure 12, the established thin-layer identification method comprises 2 reference products of daucosterol and beta-sitosterol and a cochineal flower root reference medicinal material, and has the advantages of good sample separation, proper Rf value and clear spots.
Corresponding spots are formed on the cochineal flower root medicinal material and the daucosterol and beta-sitosterol reference substances in all batches; the primula maximowiczii root medicinal material and the reference medicinal material in all batches have the same spots, and the thin-layer identification result shows that: the primula maximowiczii root herbs with numbers 6, 7, 8, 9, 10, 11, 12 and 13 are all genuine products.
The above description is only an example of the present invention, and common knowledge such as known technical means in the schemes is not described herein too much. It should be noted that, for those skilled in the art, without departing from the present invention, several changes and modifications can be made, which should also be regarded as the protection scope of the present invention, and these will not affect the effect of the implementation of the present invention and the practicability of the patent. The scope of the claims of the present application shall be defined by the claims, and the description of the embodiments and the like in the specification shall be used to explain the contents of the claims.
The present invention has been described in detail with reference to the embodiments and the accompanying drawings, wherein the principles and embodiments of the present invention are described in detail with reference to specific embodiments, which are provided to assist in understanding the methods and the core concepts of the present invention. Meanwhile, those skilled in the art should also be able to make modifications or variations to the embodiments and applications of the present invention based on the idea of the present invention. In view of the above, the present disclosure should not be construed as limiting the invention.
Claims (22)
1. A thin-layer identification method of a medicinal material nopaline comprises the following steps:
(1) Respectively pretreating a medicinal material primula maximowiczii root sample to be identified in the same way to obtain a test solution, and pretreating a reference medicinal material sample to obtain a reference medicinal material solution; and
(2) Carrying out thin-layer chromatography identification analysis on the test solution and the reference medicinal material solution;
wherein, in the step of the thin-layer chromatography identification analysis, toluene-ethyl acetate-acetone is adopted as a developing solvent, the volume ratio of the toluene to the ethyl acetate to the acetone is 4: 2-4: 2,
wherein the developing agent further comprises an acid, and the volume of the acid is 2.5% to 3.5% relative to the sum of the volumes of toluene, ethyl acetate, and acetone,
wherein the pretreatment comprises adding organic solvent into sample powder for 5-50 min, filtering, evaporating filtrate, dissolving residue with organic solvent to obtain corresponding sample solution,
wherein the organic solvent is one or more of methanol, ethanol, n-butanol, and ethyl acetate.
2. A thin-layer identification method for distinguishing a medicinal material carmine root from a medicinal material himalayan Mirabilis root comprises the following steps:
(1) Respectively pretreating a medicinal material primula maximowiczii root sample to obtain a primula maximowiczii root sample solution, and pretreating a medicinal material himalayan mirabilis root sample to obtain a himalayan mirabilis root sample solution in the same mode; and
(2) Carrying out thin-layer chromatography identification analysis on the primula maximowiczii root sample solution and the himalayan mirabilis root sample solution;
wherein, in the step of the thin-layer chromatography identification analysis, toluene-ethyl acetate-acetone is adopted as a developing solvent, the volume ratio of the toluene to the ethyl acetate to the acetone is 4: 2-4: 2,
wherein the developing agent further comprises an acid, and the volume of the acid is 2.5% to 3.5% relative to the sum of the volumes of toluene, ethyl acetate, and acetone,
wherein the pretreatment comprises adding organic solvent into sample powder for 5-50 min, filtering, evaporating filtrate, dissolving residue with organic solvent to obtain corresponding sample solution,
wherein the organic solvent is one or more of methanol, ethanol, n-butanol, and ethyl acetate.
3. A thin layer identification method of a hemorrhoid treatment capsule containing a medicinal material nopaline root comprises the following steps:
(1) Respectively pretreating a hemorrhoid treatment capsule sample to be identified in the same way to obtain a test solution, pretreating a reference medicinal material to obtain a reference medicinal material solution, and preparing the reference solution; and
(2) Carrying out thin-layer chromatography identification analysis on the test solution and the reference medicinal material solution or the reference solution;
wherein, in the step of the thin-layer chromatography identification analysis, toluene-ethyl acetate-acetone is adopted as a developing solvent, the volume ratio of the toluene to the ethyl acetate to the acetone is 4: 2-4: 2,
wherein the developing agent further comprises an acid, and the volume of the acid is 2.5% to 3.5% relative to the sum of the volumes of toluene, ethyl acetate, and acetone,
wherein the pretreatment comprises the steps of adding an organic solvent into sample powder for treatment for 5-50 minutes, filtering, evaporating filtrate to dryness, and dissolving residues by adding the organic solvent to obtain a corresponding sample solution;
wherein the concentration of the control solution is 0.15mg/mL to 0.30mg/mL,
wherein the organic solvent is one or more of methanol, ethanol, n-butanol, and ethyl acetate.
4. The thin layer identification method of any one of claims 1 to 3, wherein the acid is an organic acid.
5. The thin layer identification method of claim 4, wherein the organic acid is formic acid and/or acetic acid.
6. The lamina identification method of any one of claims 1 to 3 wherein the lamina identification method further comprises a lamina plate activation step.
7. The lamina identification method of claim 6 wherein the lamina plate activation step comprises activating the lamina plate at 100 ℃ to 120 ℃ for 20 minutes to 60 minutes.
8. The thin layer identification method of claim 6, wherein the thin layer plate is selected from a silica gel G thin layer plate, a silica gel GF thin layer plate 254 Thin layer plate, silica gel H thin layer plate, silica gel HF 254 At least one of a laminate sheet and a polyamide laminate sheet.
9. The thin layer identification method of any one of claims 1 to 3, wherein the inspection conditions in the step of thin layer chromatography identification analysis are: and (4) observing under visible light.
10. The thin layer identification method according to claim 9, wherein the developed thin layer plate is taken out during inspection, dried in the air, and sprayed with a 5% to 10% sulfuric acid ethanol solution or a 5% to 25% phosphomolybdic acid ethanol solution for color development.
11. The thin layer identification method as claimed in claim 10, wherein the developed thin layer plate is taken out during inspection, dried in the air, and sprayed with 5% to 10% sulfuric acid ethanol solution for color development.
12. The thin layer identification method as claimed in any one of claims 1 to 3, wherein the sample solution is spotted in an amount of 3 μ L to 10 μ L.
13. The thin layer identification method of claim 3, wherein the control solution is applied in an amount of 5 to 10 μ L.
14. The thin layer authentication method as claimed in any one of claims 1 to 3, wherein the treatment time is 10 to 45 minutes.
15. The thin layer identification method of any one of claims 1 to 3, wherein the treatment time is 20 to 30 minutes.
16. The thin layer identification method according to any one of claims 1 to 3, wherein the treatment method is any one or more of sonication, reflux, decoction, and dipping.
17. The thin-layer identification method of claim 3, wherein the control is daucosterol and/or β -sitosterol.
18. The thin-layer identification method according to claim 1 or 3, wherein the control drug is a cochineal root control drug.
19. Use of the thin-layer identification method according to any one of claims 1 to 18 for identifying the medicinal material nopaline root or for identifying a hemorrhoid treatment capsule comprising the medicinal material nopaline root.
20. A kit for identifying medicinal material primula maximowiczii or a hemorrhoid treatment capsule containing the medicinal material primula maximowiczii comprises a thin layer plate and a developing agent; adopting toluene-ethyl acetate-acetone as the developing agent; the volume ratio of the toluene to the ethyl acetate to the acetone is 4: 2-4: 2; the developing agent further comprises an acid; the acid is present in a proportion of 2.5% to 3.5% by volume relative to the sum of the volumes of toluene, ethyl acetate and acetone.
21. The kit of claim 20, wherein the acid is an organic acid.
22. The kit of claim 21, wherein the organic acid is formic acid and/or acetic acid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110177404.8A CN113759064B (en) | 2021-02-07 | 2021-02-07 | Thin-layer identification method for medicinal material carmine flower root and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110177404.8A CN113759064B (en) | 2021-02-07 | 2021-02-07 | Thin-layer identification method for medicinal material carmine flower root and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113759064A CN113759064A (en) | 2021-12-07 |
| CN113759064B true CN113759064B (en) | 2022-11-08 |
Family
ID=78786609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110177404.8A Active CN113759064B (en) | 2021-02-07 | 2021-02-07 | Thin-layer identification method for medicinal material carmine flower root and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113759064B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1621836A (en) * | 2004-12-13 | 2005-06-01 | 贵阳云岩西创药物科技开发有限公司 | Quality controlling method for pulse restoring injection |
| CN101584809A (en) * | 2009-07-20 | 2009-11-25 | 甘肃奇正藏药有限公司 | Medicine for treating cold grasserie and method of preparing the medicine |
| CN102590432A (en) * | 2009-07-20 | 2012-07-18 | 甘肃奇正藏药有限公司 | Detection method for medicine for curing cold nature yellow water disease |
| CN111122732A (en) * | 2019-12-27 | 2020-05-08 | 贵州景峰注射剂有限公司 | Quality detection method for caulis mahoniae medicine |
-
2021
- 2021-02-07 CN CN202110177404.8A patent/CN113759064B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1621836A (en) * | 2004-12-13 | 2005-06-01 | 贵阳云岩西创药物科技开发有限公司 | Quality controlling method for pulse restoring injection |
| CN101584809A (en) * | 2009-07-20 | 2009-11-25 | 甘肃奇正藏药有限公司 | Medicine for treating cold grasserie and method of preparing the medicine |
| CN102590432A (en) * | 2009-07-20 | 2012-07-18 | 甘肃奇正藏药有限公司 | Detection method for medicine for curing cold nature yellow water disease |
| CN111122732A (en) * | 2019-12-27 | 2020-05-08 | 贵州景峰注射剂有限公司 | Quality detection method for caulis mahoniae medicine |
Non-Patent Citations (1)
| Title |
|---|
| 藏药喜马拉雅紫茉莉的薄层鉴别方法学研究;林辉等;《世界科学技术-中医药现代化》;20141220;第16卷(第12期);第2.1.1-2.1.3、2.1.7.3、2.1.8节，第2.2节 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113759064A (en) | 2021-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wan et al. | Simultaneous determination of nine saponins from Panax notoginseng using HPLC and pressurized liquid extraction | |
| CN107505427B (en) | Thin-layer chromatography detection method for traditional Chinese medicine rheum palmatum | |
| CN108152437A (en) | American Ginseng reference extract and its preparation method and application | |
| Peishan et al. | HPTLC fingerprint identification of commercial ginseng drugs‐reinvestigation of HPTLC of ginsenosides | |
| CN113759064B (en) | Thin-layer identification method for medicinal material carmine flower root and application thereof | |
| CN115837063B (en) | Preparation and detection methods of lung force cough pharmaceutical composition | |
| CN109459515B (en) | Herba epimedii control extract (arrow leaf) and application thereof | |
| AU2020101360A4 (en) | Detection method for mold contamination in traditional chinese medicinal material | |
| CN113484429B (en) | Method for establishing standard of peach pit qi-bearing soup material | |
| CN101700306A (en) | Quality control method of Rupixiao preparation | |
| CN112730724B (en) | Thin-layer identification method for cynanchum glaucescens formula granules | |
| CN106501440B (en) | The discrimination method of field pennycress in Chinese medicine compound prescription | |
| CN107843683B (en) | The TLC Identification of Chinese trumpet creeper medicinal material | |
| CN112697950A (en) | Thin-layer chromatography identification method of pyrrosia lingua | |
| CN114487159B (en) | Detection method for fritillary bulb lung-heat clearing syrup | |
| CN108267537A (en) | A kind of method of Cortex Phellodendri in discriminating shangqing pill | |
| CN106248856B (en) | The discrimination method of active ingredient in a kind of gingko leaf preparation | |
| CN1951416A (en) | Quality control method of a compound Chinese medicinal preparation | |
| CN114217004B (en) | Windproof detection method based on thin-layer chromatography | |
| CN118091008A (en) | Thin-layer identification method of Chinese chive seed medicinal material | |
| CN114414723B (en) | Thin-layer full-medicine taste identification method for Xinkeshu tablets | |
| CN114487251B (en) | Thin-layer chromatography detection method for agilawood Shu Yupian | |
| CN115166126A (en) | Rapid thin-layer identification method for agastache rugosus stomach-clearing tablets | |
| CN118655263A (en) | Thin layer identification method for one-plate multi-measurement of Jiawei Xiaoyao pills and application thereof | |
| Salunke et al. | RECENT SCENARIO IN HERBAL TECHNOLOGY |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A thin-layer identification method and its application for the root of a medicinal herb called cochineal flower Granted publication date: 20221108 Pledgee: Qiannan Buyei and Miao Autonomous Prefecture Branch of Postal Savings Bank of China Ltd. Pledgor: GUIZHOU FUHUA PHARMACEUTICAL Co.,Ltd. Registration number: Y2024980009161 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |